Filtered By:
Condition: Ischemic Stroke
Nutrition: Vitamin K
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 706 results found since Jan 2013.
Management of stroke in patients on antithrombotic therapy: Practical issues in the era of direct oral anticoagulants
Rev Neurol (Paris). 2021 Oct 20:S0035-3787(21)00707-4. doi: 10.1016/j.neurol.2021.07.021. Online ahead of print.ABSTRACTAntithrombotic drugs (ADs) are the mainstay of secondary prevention of thrombotic vascular diseases. Management of patients under long-term treatment with ADs admitted for acute cerebrovascular disease, either ischemic stroke (IS) or intracerebral hemorrhage (ICH), has become a frequent situation that might influence decision-making processes from diagnosis to therapeutic strategies. The aim of this review is to summarize current data from the literature to help clinicians in their decisions for stroke ca...
Source: Revue Neurologique - October 24, 2021 Category: Neurology Authors: I Sibon J S Liegey Source Type: research
Intravenous Thrombolytic Therapy for Treatment of Acute Ischemic Stroke in Patients Taking NOACs
Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (alteplase) is the cornerstone of acute ischemic stroke reperfusion therapy and is associated with significant improvements in outcomes. Historically, a number of exclusion criteria for use of alteplase had been in place, but over the past 20 years, some of these have been eliminated (eg, age>80 years, seizures at stroke onset) or have become less stringent (eg, exclusion criteria may not strictly apply to recent vitamin K antagonist treatment if the patient has an international normalized ratio<1.7, and treatment may be administered in an...
Source: JAMA - February 22, 2022 Category: General Medicine Source Type: research
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries
CONCLUSIONS: Incidences of intracranial bleeding were generally lower with rivaroxaban than with SOC, whereas incidences of gastrointestinal and urogenital bleeding were generally higher. The safety profile of rivaroxaban for NVAF in routine practice is consistent with findings from randomized controlled trials and other studies.PMID:36795067 | DOI:10.1080/14740338.2023.2181334
Source: Expert Opinion on Drug Safety - February 16, 2023 Category: Drugs & Pharmacology Authors: Luis Alberto Garc ía-Rodríguez Ana Ruig ómez Tania Schink Annemarie Voss Elisabeth Smits Karin M A Swart Yanina Balabanova Kiliana Suzart-Woischnik Gunnar Brobert Ron M C Herings Source Type: research
Survey on APS diagnosis and antithrombotic treatment in patients with ischaemic stroke, other brain ischaemic injury or arterial thromboembolism in other sites: Communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies (LA/aPL)
CONCLUSIONS: Much of the variation in practice reflects the lack of evidence-based recommendations. The survey results should inform the development of a more uniform multidisciplinary consensus approach to diagnosis and antithrombotic treatment.PMID:37391096 | DOI:10.1016/j.jtha.2023.06.020
Source: Thrombosis and Haemostasis - June 30, 2023 Category: Hematology Authors: Hannah Cohen David J Werring Arvind Chandretheva Prabal Mittal Katrien M J Devreese David A Isenberg ISTH SSC LA/aPL Subcommittee Study Group Source Type: research
In-hospital ischaemic stroke treated with intravenous thrombolysis or mechanical thrombectomy
The objective of this study is to compare outcomes in patients with IHS and community-onset strokes (COS) treated by recanalization therapy. We analysed data prospectively collected in consecutive patients treated by thrombolysis, thrombectomy, or both for cerebral ischemia at the Lille University Hospital. We compared four outcomes measures at 3 months in patients with IHS and COS: (1) modified Rankin scale (mRS) 0–1, (2) mRS 0–2, (3) death, and (4) symptomatic intracranial haemorrhage (ECASS 2 definition). Of 1209 patients, 64 (5.3%) had IHS, with an increasing proportion over time (p = 0.001). Their median onset...
Source: Journal of Neurology - July 15, 2017 Category: Neurology Source Type: research
Contemporary Management of Stroke Prevention in Atrial Fibrillation Following the European Society of Cardiology Guidelines
Prevention of ischaemic stroke has long been central to the management of patients with atrial fibrillation (AF), historically relying on the use of vitamin K antagonists (VKAs) or antiplatelet agents depending on the risk of thromboembolism. Difficulties associated with maintaining VKAs in therapeutic range and the perceived risk of bleeding have been highlighted as reasons to withhold oral anticoagulation (OAC) and these issues have partly been addressed by the introduction of non-vitamin K antagonist oral anticoagulants (NOACs).
Source: Radcliffe Cardiology - August 14, 2017 Category: Cardiology Authors: mehul Source Type: research
Antithrombotic Treatments in Patients with Acute Ischemic Stroke and Non-Valvular Atrial Fibrillation Before Introduction of Non-Vitamin K Antagonist Oral Anticoagulants Into Practice in Korea
This multicenter observational study aimed to describe patterns of long-term antithrombotic use in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF) in Korea and their impacts on clinical events before introduction of non-vitamin K antagonist oral anticoagulants (NOAC) into practice in 2015.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: H Bae, J Heo, K Jung, Y Lee, K Hong, W Seo, J Koo, J Cha, MJ Lee, B Seo, Y Kim, S Kang, J Seok, J Lee, C Chung Source Type: research
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients
Recently, non-vitamin K antagonist oral anticoagulants such as direct thrombin and direct factor Xa inhibitors have been prescribed for prevention of embolic stroke. While in Japan, argatroban, also a direct t...
Source: Clinical and Translational Medicine - January 12, 2018 Category: Internal Medicine Authors: Taizen Nakase, Junta Moroi and Tatsuya Ishikawa Tags: Research Source Type: research
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants Expert opinion of the Societe Francaise de Neurologie Vasculaire (SFNV) French Vascular Neurology Society and the Groupe Francais d'etudes sur l'Hemostase et la Thrombose (GFHT) French study Group on Haemostasis and Thrombosis
ConclusionsIn this expert opinion paper, we suggest that IVT can be performed in patients selected according to the time elapsed since the drug was last taken, renal function, type of hospital where the patient is admitted and plasma concentration of DOAC.This article is protected by copyright. All rights reserved.
Source: European Journal of Neurology - January 23, 2018 Category: Neurology Authors: Emmanuel Touz é, Yves Gruel, Isabelle Gouin‐Thibault, Emmanuel De Maistre, Sophie Susen, Pierre Sie, Laurent Derex Tags: Original Article Source Type: research
Portuguese Observational Study of Ischaemic Stroke in Patients Medicated with Non-Vitamin K Antagonist Oral Anticoagulants
Conclusion: Preadmission anticoagulation with NOACs in AIS has a functional impact similar to that of VKAs.Eur Neurol 2018;79:108 –112
Source: European Neurology - February 8, 2018 Category: Neurology Source Type: research
Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment
Whether carotid atherosclerosis is associated with an increased risk for ischemic stroke in patients with atrial fibrillation (AF) on anticoagulant treatment is undefined. To explore this association, patients with AF on treatment with vitamin K antagonists were included in a multicenter, prospective study.
Source: Atherosclerosis - February 22, 2018 Category: Cardiology Authors: Cecilia Becattini, Francesco Dentali, Giuseppe Camporese, Agnese Sembolini, Elena Rancan, Chiara Tonello, Giorgia Manina, Seena Padayattil, Giancarlo Agnelli Source Type: research
Safety of Endovascular Thrombectomy for Acute Ischaemic Stroke in Anticoagulated Patients Ineligible for Intravenous Thrombolysis
Conclusion: Mechanical thrombectomy appears to be safe and effective in anticoagulated patients ineligible for thrombolysis, with observed haemorrhage rates similar to those of patients not on anticoagulant therapy. However, further multicentre prospective studies are needed, due to the rising number of patients on warfarin and DOACs worldwide.Cerebrovasc Dis 2018;46:193 –199
Source: Cerebrovascular Diseases - November 1, 2018 Category: Neurology Source Type: research
MRI characteristics in acute ischemic stroke patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists
Despite the utility of neuroimaging in the diagnostic and therapeutic management of patients with acute ischemic stroke (AIS), imaging characteristics in patients with preceding direct oral anticoagulants (DOA...
Source: BMC Neurology - March 11, 2020 Category: Neurology Authors: Thomas Raphael Meinel, Johannes Kaesmacher, Jan Gralla, David J. Seiffge, Elias Auer, Sebasti én Frey, Marwan El-Koussy, Marcel Arnold, Urs Fischer, Martina Göldlin, Simon Jung and Arsany Hakim Tags: Research article Source Type: research
Malignant Left Atrial Appendage Morphology: Current Classification vs H-L System
In non-valvular atrial fibrillation (AF), more than 90% of thrombus formation occurs in the left atrial appendage (LAA).1-3 Current guidelines have established direct oral anticoagulants (DOACs) as the treatment of choice in patients with AF and high risk of stroke or transient ischemic attack (TIA), while vitamin K antagonists (VKA) can be considered in patients not suitable for DOACs.4,5 This strategy significantly reduces the risk of thromboembolism; however, there is a subset of patients that suffer recurrent embolic strokes despite appropriate anticoagulant therapy, known as malignant LAA.
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2020 Category: Neurology Authors: Paloma Parra-D íaz, Luisa Salido-Tahoces, Ana Pardo-Sanz, Álvaro Beltrán-Corbellini, Fernando Rodríguez-Jorge, Juan Luis Chico-García, Sebastián García-Madrona, Consuelo Matute-Lozano, Rocío Vera-Lechuga, Antonio Cruz-Culebras, Jaime Masjuan, Alic Source Type: research
Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation
Expert Opin Investig Drugs. 2021 Mar 8. doi: 10.1080/13543784.2021.1897786. Online ahead of print.ABSTRACTINTRODUCTION: Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia globally and is associated with ischemic stroke and heart failure. Patients with atrial fibrillation are typically prescribed long term anticoagulants in the form of either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants; however, both carry a potential risk of adverse bleeding.AREAS COVERED: This paper sheds light on emerging anticoagulant agents which target clotting factors XI and XII, or their activated forms...
Source: Expert Opinion on Investigational Drugs - March 8, 2021 Category: Drugs & Pharmacology Authors: Robert Bentley Lewis J Hardy Laura J Scott Parveen Sharma Helen Philippou Gregory Y H Lip Source Type: research
